Introduction to Biopharmaceutics MCQs With Answer
Biopharmaceutics explores how drug formulation, dosage form and physiological factors influence drug absorption, distribution, metabolism and excretion. This concise MCQ set for B.Pharm students emphasizes key concepts such as bioavailability, pharmacokinetics, dissolution (Noyes-Whitney), permeability, pKa and ionization, the Biopharmaceutics Classification System (BCS), first-pass metabolism, protein binding, and strategies to enhance solubility and IVIVC. These targeted questions will strengthen understanding of rate- and extent-limiting steps in drug absorption, design implications for oral and alternative routes, and interpretation of Cmax, Tmax, AUC, clearance and half-life. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What does biopharmaceutics primarily study?
- The chemical synthesis pathways of new drug molecules
- Study of relationship between drug formulation, administration route and drug absorption, distribution, metabolism and excretion
- Clinical trial design and patient recruitment strategies
- Regulatory documentation for marketing approval
Correct Answer: Study of relationship between drug formulation, administration route and drug absorption, distribution, metabolism and excretion
Q2. The Biopharmaceutics Classification System (BCS) classifies drugs based on which two properties?
- Molecular weight and melting point
- Solubility and permeability
- pKa and partition coefficient
- Protein binding and clearance
Correct Answer: Solubility and permeability
Q3. The Noyes–Whitney equation describes which process?
- Drug metabolism by hepatic enzymes
- Dissolution rate of solid drugs in a solvent
- Renal tubular secretion kinetics
- Protein binding equilibrium
Correct Answer: Dissolution rate of solid drugs in a solvent
Q4. For a BCS class II drug (low solubility, high permeability), what is usually the rate-limiting step for oral absorption?
- Membrane permeability across enterocytes
- Dissolution of the solid drug in gastrointestinal fluids
- Renal clearance
- Hepatic metabolism after absorption
Correct Answer: Dissolution of the solid drug in gastrointestinal fluids
Q5. Which principle explains the effect of pH on the proportion of ionized drug?
- Fick’s first law
- Henderson–Hasselbalch equation
- Noyes–Whitney equation
- Michaelis–Menten kinetics
Correct Answer: Henderson–Hasselbalch equation
Q6. Lipophilicity of a drug is commonly expressed as:
- pKa
- Log P (partition coefficient)
- Intrinsic dissolution rate
- Clearance
Correct Answer: Log P (partition coefficient)
Q7. What is meant by “first-pass metabolism”?
- Metabolism occurring in the bloodstream after renal filtration
- Metabolism in the liver and gut wall before the drug reaches systemic circulation
- Metabolism by skin enzymes after topical application
- Enzymatic degradation in the stomach lumen only
Correct Answer: Metabolism in the liver and gut wall before the drug reaches systemic circulation
Q8. How is absolute bioavailability (F) calculated from plasma AUCs?
- F = (AUCiv / AUCpo) × (Dosepo / Doseiv)
- F = (AUCpo / AUCiv) × (Doseiv / Dosepo)
- F = Cmaxpo / Cmaxiv
- F = Tmaxpo / Tmaxiv
Correct Answer: F = (AUCpo / AUCiv) × (Doseiv / Dosepo)
Q9. Cmax and Tmax represent which pharmacokinetic parameters?
- Area under the curve and half-life respectively
- Peak plasma concentration and time to reach peak concentration
- Volume of distribution and clearance respectively
- Bioavailability and absorption rate constant respectively
Correct Answer: Peak plasma concentration and time to reach peak concentration
Q10. AUC (area under the plasma concentration–time curve) primarily indicates:
- The maximum absorption rate only
- Total systemic exposure to the drug over time
- The drug’s toxicity threshold
- The drug’s solubility in intestinal fluids
Correct Answer: Total systemic exposure to the drug over time
Q11. Volume of distribution (Vd) is best described as:
- The physical volume of blood in the body
- An apparent volume that relates amount of drug in body to plasma concentration
- The volume of extracellular fluid only
- The volume of urine produced per hour
Correct Answer: An apparent volume that relates amount of drug in body to plasma concentration
Q12. Clearance (CL) refers to:
- The fraction of drug eliminated per dose
- The volume of plasma cleared of drug per unit time
- The drug concentration at steady state
- The time taken to excrete 50% of the dose unchanged
Correct Answer: The volume of plasma cleared of drug per unit time
Q13. The elimination half-life (t1/2) is mathematically related to Vd and CL by:
- t1/2 = CL / (0.693 × Vd)
- t1/2 = 0.693 × Vd / CL
- t1/2 = Vd × CL
- t1/2 = AUC / Dose
Correct Answer: t1/2 = 0.693 × Vd / CL
Q14. Which statement differentiates zero-order from first-order elimination?
- Zero-order elimination rate depends on concentration; first-order is constant amount removed
- Zero-order elimination removes a constant amount per unit time; first-order removes a constant fraction per unit time
- Both remove drugs proportionally to concentration
- Neither process is relevant to clinical dosing
Correct Answer: Zero-order elimination removes a constant amount per unit time; first-order removes a constant fraction per unit time
Q15. Food typically affects oral drug absorption by:
- Always increasing clearance of the drug
- Delaying gastric emptying and potentially increasing bioavailability of poorly soluble lipophilic drugs
- Preventing intestinal absorption permanently
- Neutralizing all weak acids in the stomach
Correct Answer: Delaying gastric emptying and potentially increasing bioavailability of poorly soluble lipophilic drugs
Q16. Enterohepatic recirculation causes which pharmacokinetic phenomenon?
- Complete drug elimination without reabsorption
- Secondary peaks in plasma concentration–time profile due to biliary excretion and intestinal reabsorption
- Immediate renal excretion of conjugated metabolites only
- Permanent inactivation of the parent drug in the gut lumen
Correct Answer: Secondary peaks in plasma concentration–time profile due to biliary excretion and intestinal reabsorption
Q17. High plasma protein binding of a drug generally results in:
- Increased free fraction and enhanced immediate pharmacologic effect
- Reduced free fraction and limited distribution to tissues
- Complete prevention of renal excretion
- Faster hepatic metabolism due to binding
Correct Answer: Reduced free fraction and limited distribution to tissues
Q18. Which route across the intestinal epithelium is most common for small lipophilic drugs?
- Paracellular aqueous diffusion only
- Transcellular passive diffusion through enterocyte membranes
- Active carrier-mediated influx exclusively
- Endocytosis in the colon
Correct Answer: Transcellular passive diffusion through enterocyte membranes
Q19. P-glycoprotein (P-gp) in the intestinal epithelium primarily:
- Enhances passive diffusion of lipophilic drugs
- Acts as an efflux transporter reducing oral absorption of some drugs
- Is responsible for drug conjugation reactions
- Increases stability of drugs in gastric acid
Correct Answer: Acts as an efflux transporter reducing oral absorption of some drugs
Q20. Which formulation strategy is commonly used to improve aqueous solubility of a weakly basic drug?
- Forming a salt of the drug
- Increasing particle size
- Removing surfactants from the formulation
- Decreasing temperature of storage below freezing
Correct Answer: Forming a salt of the drug
Q21. In vitro–in vivo correlation (IVIVC) refers to:
- Correlation between dissolution profile and clinical side effects
- Predictive relationship between in vitro dissolution and in vivo absorption/performance
- No relationship between lab tests and human data
- Correlation between animal toxicology and human efficacy only
Correct Answer: Predictive relationship between in vitro dissolution and in vivo absorption/performance
Q22. Dissolution testing is most critical to predict bioavailability for which BCS class?
- BCS Class I (high solubility, high permeability)
- BCS Class II (low solubility, high permeability)
- BCS Class III (high solubility, low permeability)
- BCS Class IV (low solubility, low permeability) where dissolution is irrelevant
Correct Answer: BCS Class II (low solubility, high permeability)
Q23. Gastroretentive drug delivery systems are particularly useful for drugs that:
- Are absorbed primarily in the colon
- Have a narrow absorption window in the stomach or proximal small intestine
- Undergo extensive renal secretion unchanged
- Are unstable at low pH
Correct Answer: Have a narrow absorption window in the stomach or proximal small intestine
Q24. Which route of administration bypasses hepatic first-pass metabolism?
- Oral (swallowed) route
- Sublingual/transmucosal route
- Enteric-coated oral tablets
- Gastric tube administration
Correct Answer: Sublingual/transmucosal route
Q25. The main purpose of designing a prodrug is to:
- Increase the molecular weight permanently
- Improve absorption, permeability or stability and be converted to the active drug in vivo
- Prevent the drug from binding to plasma proteins ever
- Eliminate the need for hepatic metabolism entirely
Correct Answer: Improve absorption, permeability or stability and be converted to the active drug in vivo
Q26. Renal excretion of drugs involves which processes?
- Only glomerular filtration
- Glomerular filtration, active tubular secretion, and tubular reabsorption
- Only passive diffusion into urine
- Only metabolism by renal enzymes
Correct Answer: Glomerular filtration, active tubular secretion, and tubular reabsorption
Q27. According to pH-partition theory, a weak acid is better absorbed in which region?
- In the alkaline intestinal lumen where it is ionized
- In the acidic stomach where it remains largely unionized
- Only in the colon irrespective of pH
- Only after conjugation in the liver
Correct Answer: In the acidic stomach where it remains largely unionized
Q28. For drugs with high hepatic extraction ratio, hepatic clearance is most dependent on:
- Protein binding only
- Hepatic blood flow
- Intrinsic enzyme activity regardless of blood flow
- Renal tubular secretion
Correct Answer: Hepatic blood flow
Q29. Displacement of a highly protein-bound drug by another drug can lead to:
- Decreased free plasma concentration and reduced effect
- Increased free (unbound) concentration and potential toxicity
- Complete prevention of hepatic metabolism
- No clinically relevant change in pharmacodynamics
Correct Answer: Increased free (unbound) concentration and potential toxicity
Q30. Use of surfactants in dissolution media is intended to:
- Simulate bile salt action and improve apparent solubility of lipophilic drugs
- Decrease drug dissolution by forming insoluble complexes
- Increase drug protein binding in vitro
- Prevent any drug absorption in vivo
Correct Answer: Simulate bile salt action and improve apparent solubility of lipophilic drugs
